सर्वोत्तम Pharma & Healthcare फंड
Defensive-growth exposure to pharma, hospitals and diagnostics.
डेटा अपडेट · 18 डायरेक्ट-ग्रोथ फंड, 0–100 Smart Score ने रँक केलेले
खालील इंटरॲक्टिव्ह टेबल इंग्रजीत आहे — आकडे आणि फंडांची नावे दोन्ही भाषांत सारखीच.
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities SBI | 79 | Strong Buy | 21.3% | 24.7% | 18.3% | 1.26 | 2.02 | 14.4 | 5.3 | 0.83 | — | 55.6 | 1.02% | ₹5.4k Cr | 13.7y | |
| HDFC Pharma And Healthcare HDFC | 79 | Strong Buy | 26.9% | — | — | 1.82 | 2.61 | 14.0 | 21.0 | 0.66 | — | 49.8 | 1.11% | ₹2.9k Cr | 2.9y | |
| UTI Healthcare UTI | 68 | Buy | 18.3% | 25.1% | 16.2% | 1.16 | 1.98 | 16.0 | 4.6 | 0.90 | — | 42.6 | 1.28% | ₹1.4k Cr | 13.7y | |
| Kotak Healthcare Kotak | 64 | Buy | 27.2% | — | — | 1.16 | 1.64 | 14.4 | 14.6 | 0.68 | — | 50.4 | 1.09% | ₹676 Cr | 2.7y | |
| Mirae Asset Healthcare Mirae Asset | 59 | Hold | 20.3% | 23.4% | 15.4% | 1.09 | 1.71 | 16.2 | 3.0 | 0.94 | — | 47.9 | 0.61% | ₹3.4k Cr | 8.2y | |
| DSP Healthcare DSP | 58 | Hold | 17.9% | 22.5% | 15.4% | 1.10 | 1.78 | 14.9 | 4.3 | 0.79 | — | 35.4 | 0.71% | ₹3.6k Cr | 7.8y | |
| PGIM India Healthcare PGIM India | 51 | Hold | 24.7% | — | — | 0.55 | 0.75 | 13.1 | 10.4 | 0.66 | — | 56.6 | 0.92% | ₹112 Cr | 1.8y | |
| ICICI Pru Healthcare ICICI Pru | 49 | Hold | 9.2% | 23.2% | 15.9% | 1.08 | — | 16.2 | 3.4 | 0.91 | — | — | 1.33% | ₹6.8k Cr | 8.2y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 47 | Hold | 22.0% | — | — | 0.39 | 0.53 | 13.4 | 6.5 | 0.68 | — | 52.8 | 0.88% | ₹377 Cr | 1.7y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 46 | Hold | 22.0% | — | — | — | — | — | — | — | — | 51.3 | 1.16% | ₹825 Cr | 2.6y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 45 | Hold | 17.8% | 22.7% | 14.2% | 1.09 | 1.82 | 15.3 | 2.8 | 0.90 | — | 47.6 | 1.01% | ₹1.1k Cr | 7.2y | |
| Nippon India Pharma Nippon India | 41 | Avoid | 11.7% | 19.4% | 13.5% | 0.99 | 1.43 | 13.0 | 9.1 | 0.59 | — | 40.4 | 1.00% | ₹9.3k Cr | 13.7y | |
| ITI Pharma And Healthcare ITI | 39 | Avoid | 13.1% | 20.5% | — | 0.99 | 1.39 | 14.2 | 9.8 | 0.67 | — | 47.6 | 0.98% | ₹263 Cr | 4.8y | |
| LIC MF Healthcare LIC | 37 | Avoid | 17.1% | 23.4% | 12.5% | 1.11 | 1.72 | 15.9 | 4.0 | 0.88 | — | 52.3 | 1.42% | ₹98 Cr | 7.5y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 37 | Avoid | 11.0% | — | — | 0.08 | 0.12 | 11.4 | 4.3 | 0.56 | — | 47.3 | 1.04% | ₹519 Cr | 1.2y | |
| Tata India Pharma & Healthcare Tata | 33 | Avoid | 10.1% | 20.7% | 14.6% | 0.93 | 1.53 | 16.4 | -0.0 | 0.98 | — | 44.7 | 0.97% | ₹1.5k Cr | 10.7y | |
| Quant Healthcare Quant | 23 | Avoid | 22.1% | 21.7% | — | 0.91 | 1.22 | 18.2 | 2.7 | 0.89 | — | 41.2 | 1.51% | ₹389 Cr | 3.2y | |
| Bandhan Healthcare Bandhan | 22 | Avoid | — | — | — | — | — | — | — | — | — | 43.0 | 1.20% | ₹319 Cr | 0.8y |
Pharma & Healthcare — झटपट उत्तरे
›सध्या सर्वोत्तम Pharma & Healthcare म्युच्युअल फंड कोणता आहे?
SBI Healthcare Opportunities सध्या 18 Pharma & Healthcare फंडांमध्ये #1 आहे — FundLens Smart Score 79/100 (Strong Buy). 3 वर्षांचा रिटर्न 24.7%, 5 वर्षांचा 18.3%, एक्स्पेन्स रेशो 1.02% (डायरेक्ट प्लॅन). रँकिंग 07 Sept 2026 च्या डेटावर आधारित.
›कोणत्या Pharma & Healthcare फंडाचा रिस्क-ॲडजस्टेड रिटर्न सर्वोत्तम आहे?
सॉर्टिनो रेशोनुसार HDFC Pharma And Healthcare कॅटेगरीत सर्वात पुढे — 2.61 (शार्प 1.82). म्हणजे घसरणीच्या प्रत्येक युनिट रिस्कवर सर्वाधिक रिटर्न.
›सर्वात कमी एक्स्पेन्स रेशो असलेला Pharma & Healthcare फंड कोणता?
Mirae Asset Healthcare — वार्षिक 0.61% (डायरेक्ट प्लॅन), कॅटेगरीत सर्वात कमी. कमी फी दीर्घकाळात तुमच्या बाजूने कम्पाउंड होते.
›AUM नुसार सर्वात लहान Pharma & Healthcare फंड कोणता?
LIC MF Healthcare — ₹98 Cr, कॅटेगरीत सर्वात लहान. लहान फंड चपळ असू शकतात, पण फक्त साइझला गुण मानू नका.
›Pharma & Healthcare फंडात किती काळ गुंतवणूक ठेवावी?
Pharma & Healthcare फंडांचा रिस्क खूप जास्त असतो, म्हणून साधारण 7+ वर्षे चा दृष्टिकोन शहाणपणाचा. Defensive-growth exposure to pharma, hospitals and diagnostics. हे संशोधन आहे, गुंतवणूक सल्ला नाही.
हीच उत्तरे गप्पांमध्ये हवीत? FundLens ला विचारा